Cell Therapeutics, Inc. (NASDAQ: CTIC) is focused on leading the biopharmaceutical industry with their diversified portfolio of proprietary oncology drugs. They manage each and every aspect of the manufacturing process, but outsource their clinical and commercial active pharmaceutical ingredient (API) and finished product (FP) production activities to superior contract manufacturing organizations, both in the US and in Europe. For further information, visit the Company’s web site at www.ctiseattle.com.
- 17 years ago
QualityStocks
Cell Therapeutics, Inc. (NASDAQ: CTIC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Secures Up to $100 Million in Project Financing for 97 MW U.S. Solar Portfolio
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has…
-
QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Bollinger Delivers EV Truck to LES Ecology Center
Mullen Automotive (NASDAQ: MULN) announced that its subsidiary, Bollinger Motors, has delivered a Bollinger B4…
-
QualityStocksNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) CEO to Present Live via Skyline Signature Series on May 7
FingerMotion (NASDAQ: FNGR), a mobile services, data and technology company, announced that CEO Martin J.…